01.20.09
Johnson & Johnson today announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6%, according to the company.
Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007. Operational results declined 1.0% and the negative impact of currency was 3.9%. Domestic sales decreased 6.9%, while international sales decreased 2.7%, reflecting operational growth of 5.4%, says the report.
Net earnings for the year 2008 were $12.9 billion, while net earnings for the fourth quarter of 2008 were $2.7 billion. Last year's net earnings were not released in the report to offer a percentage comparison.
"I am extremely proud of Johnson & Johnson's accomplishments in 2008 and the way our people met our commitments," said William C. Weldon, company chairman and chief executive officer. "We delivered solid earnings growth and made significant progress in our research pipelines while continuing to invest in the future growth of our business. I am confident that we are well positioned for continued leadership and growth in health care."
Sales results reflect the strong performance of skin care lines Neutrogena, Aveeno and Clean & Clear; international sales of baby care products; and Listerine antiseptic mouthrinse. Also contributing to growth were sales from the recently completed acquisition of Dabao, a leading moisturizer in China, says the company.
Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007. Operational results declined 1.0% and the negative impact of currency was 3.9%. Domestic sales decreased 6.9%, while international sales decreased 2.7%, reflecting operational growth of 5.4%, says the report.
Net earnings for the year 2008 were $12.9 billion, while net earnings for the fourth quarter of 2008 were $2.7 billion. Last year's net earnings were not released in the report to offer a percentage comparison.
"I am extremely proud of Johnson & Johnson's accomplishments in 2008 and the way our people met our commitments," said William C. Weldon, company chairman and chief executive officer. "We delivered solid earnings growth and made significant progress in our research pipelines while continuing to invest in the future growth of our business. I am confident that we are well positioned for continued leadership and growth in health care."
Sales results reflect the strong performance of skin care lines Neutrogena, Aveeno and Clean & Clear; international sales of baby care products; and Listerine antiseptic mouthrinse. Also contributing to growth were sales from the recently completed acquisition of Dabao, a leading moisturizer in China, says the company.